Independent Gateway to Understanding Type 2 Inflammation
Chronic rhinosinusitis with nasal polyps (CRSwNP) is a heterogeneous, inflammatory disease with defects in the epithelial barrier [1-5]. After treatment with corticosteroids as first-line therapy and endoscopic sinus surgery (ESS) when first-line therapy fails, recurrence occurs in over 50% of patients [1,6-13]. To improve disease management, it is necessary to identify predictors of recurrence. Currently used biomarkers require tissue harvesting, which…
Ghadersohi S, Price CPE, Jensen SE, et al. Development and Preliminary Validation of a New Patient-Reported Outcome Measure for Chronic Rhinosinusitis (CRS-PRO). J Allergy Clin Immunol Pract. 2020;8(7):2341-2350.e1. Chronic rhinosinusitis (CRS) is an inflammatory disease of the nasal airways and paranasal sinuses with a high disease burden [1,2]. Patient-reported outcome (PRO) instruments are measures of disease severity and symptom burden in…
Young HY, Sun HE, et al. Altered Mitochondrial Functions and Morphologies in Epithelial Cells Are Associated With Pathogenesis of Chronic Rhinosinusitis With Nasal Polyps. Allergy Asthma Immunol Res. 2020 Jul;12(4):653-668 Chronic rhinosinusitis with nasal polyps (CRSwNP) is a complex inflammatory disease of the nasal and paranasal sinus mucosa [1]. There are indications that the disease is associated with mitochondrial dysfunction,…
Chronic rhinosinusitis with nasal polyps (CRSwNP) is a chronic inflammatory condition of the sinonasal cavities [1-3]. It is frequently comorbid with asthma and both diseases share common underlying pathophysiological mechanisms driving the disease, including type 2 inflammation [3-9]. CRSwNP severely impacts quality of life and has a significant burden on society [10-12]. When symptoms are persistent or when there is…
Chronic rhinosinusitis with nasal polyposis (CRSwNP) is one of the most severe forms of chronic rhinosinusitis. CRSwNP is characterized by nasal and facial congestion, loss of sense of smell, rhinorrhea, and post-nasal drip. Treatments have been ineffective at controlling disease recurrence, despite multiple courses of medical and surgical therapies. Oral glucocorticoid therapy is often used to control exacerbations leaving the…
In a pooled analysis of the SINUS-24 and SINUS-52 trials, dupilumab significantly improved both upper and lower airway outcomes compared with placebo in patients with severe chronic rhinosinusitis with nasal polyps and comorbid asthma [1]. Dr Jorge Maspero (Fundación CIDEA, Argentina) presented the research in a late-breaking clinical trial session, pointing out that asthma and chronic rhinosinusitis with nasal polyps…